Dana-Farber Cancer Institute Settles Fraud Allegations for $15 Million

Dana-Farber Cancer Institute, a prominent cancer research and treatment center based in Boston, has agreed to pay $15 million to settle allegations of research misconduct related to false statements and certifications concerning its scientific publications. The allegations, which span from 2014 to 2024, involve the misuse of images and data in 14 journal articles, leading to misinformation in the scientific community. The settlement was reached under the False Claims Act, which allows private individuals to sue on behalf of the government for fraud involving federal funds.

WBTS - NBC 10 - Boston

The U.S. Attorney's Office for Massachusetts reported that Dana-Farber's researchers misrepresented and duplicated images and data in their publications. Specific practices included reusing images to depict different experimental conditions and altering images through rotation or magnification. The settlement also revealed that a supervising researcher failed to provide adequate oversight, resulting in the improper use of funds from six National Institutes of Health (NIH) grants. Additionally, four NIH grants were awarded based on applications that referenced one of the flawed journal articles without disclosing the data manipulation.

WBTS - NBC 10 - BostonBoston HeraldRetraction Watch

The allegations were initially brought to light by whistleblower Sleuth Sholto David, who published a series of blog posts highlighting potential data manipulation in Dana-Farber's research. Following these revelations, Dana-Farber retracted six studies and corrected 31 others. The original complaint included 95 studies, implicating senior leaders at the institution, including President and CEO Laurie Glimcher.

Retraction Watch

Dana-Farber has stated that it fully cooperated with the investigation and emphasized its commitment to research integrity. A spokesperson noted, "Neither the settlement, nor the related lawsuit, alleged any impact on clinical trials or patient care." U.S. Attorney Leah Foley remarked on the importance of maintaining integrity in scientific research, stating, "There is no place in scientific research, particularly cancer research, for fraud, waste, and abuse."

WBTS - NBC 10 - Boston

While the settlement has been viewed as a necessary step towards accountability, some critics argue that it highlights systemic issues within research institutions regarding oversight and data integrity. Whistleblower attorney Renée Brooker emphasized the need for increased awareness among researchers about the importance of reporting fraud, suggesting that many may not fully understand the implications of the False Claims Act.

Retraction Watch

• “Our commitment to research integrity is at the core of everything we do,” — Benjamin Ebert, President and CEO of Dana-Farber

Boston Herald

• “The False Claims Act is a great watchdog, if you will, for exactly this type of fraud,” — Renée Brooker, Whistleblower Attorney

Retraction Watch

• “The case was filed in 2024. In False Claims Act-speak, usually cases take at least three years from the filing to some resolution, and usually much longer than that. I think that’s another good indication that this administration is still prioritizing much of the same kinds of fraud objectives and enforcement actions that we’ve known for the last decade plus.” — Eva Gunasekera, Whistleblower Attorney

Retraction Watch

The Dana-Farber settlement underscores the ongoing scrutiny of research integrity within institutions receiving federal funding. As the NIH continues to enforce compliance with grant conditions, this case may serve as a precedent for future investigations into research misconduct. The settlement funds will primarily be directed back to the NIH to support legitimate scientific research, reinforcing the importance of transparency and accountability in the field.

Boston Herald